TY - JOUR
T1 - High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort
AU - González Briceño, Laura Gabriela
AU - Kariyawasam, Dulanjalee
AU - Samara-Boustani, Dinane
AU - Giani, Elisa
AU - Beltrand, Jacques
AU - Bolle, Stéphanie
AU - Fresneau, Brice
AU - Puget, Stéphanie
AU - Sainte-Rose, Christian
AU - Alapetite, Claire
AU - Pinto, Graziella
AU - Piketty, Marie Liesse
AU - Brabant, Séverine
AU - Abbou, Samuel
AU - Aerts, Isabelle
AU - Beccaria, Kevin
AU - Bourgeois, Marie
AU - Roujeau, Thomas
AU - Blauwblomme, Thomas
AU - Di Rocco, Federico
AU - Thalassinos, Caroline
AU - Pauwels, Christian
AU - Rigaud, Charlotte
AU - James, Syril
AU - Busiah, Kanetee
AU - Simon, Albane
AU - Bourdeaut, Franck
AU - Lemelle, Lauriane
AU - Guerrini-Rousseau, Léa
AU - Orbach, Daniel
AU - Touraine, Philippe
AU - Doz, François
AU - Dufour, Christelle
AU - Grill, Jacques
AU - Polak, Michel
N1 - Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Context: Endocrine complications are common in pediatric brain tumor patients. Objective: We aimed to describe the endocrine follow-up of patients with primary brain tumors. Methods: This is a noninterventional observational study based on data collection from medical records of 221 patients followed at a Pediatric Endocrinology Department. Results: Median age at diagnosis was 6.7 years (range, 0-15.9), median follow-up 6.7 years (0.3-26.6), 48.9% female. Main tumor types were medulloblastoma (37.6%), craniopharyngioma (29.0%), and glioma (20.4%). By anatomic location, 48% were suprasellar (SS) and 52% non-suprasellar (NSS). Growth hormone deficiency (GHD) prevalence was similar in both groups (SS: 83.0%, NSS: 76.5%; P = 0.338), appearing at median 1.8 years (-0.8 to 12.4) after diagnosis; postradiotherapy GHD appeared median 1.6 years after radiotherapy (0.2-10.7). Hypothyroidism was more prevalent in SS (76.4%), than NSS (33.9%) (P < 0.001), as well as ACTH deficiency (SS: 69.8%, NSS: 6.1%; P < 0.001). Early puberty was similar in SS (16%) and NSS (12.2%). Hypogonadotropic hypogonadism was predominant in SS (63.1%) vs NSS (1.3%), P < 0.001, and postchemotherapy gonadal toxicity in NSS (29.6%) vs SS (2.8%), P < 0.001. Adult height was lower for NSS compared to target height (-1.0 SD, P < 0.0001) and to SS patients (P < 0.0001). Thyroid nodules were found in 13/45 patients (28.8%), including 4 cancers (4.8-11.5 years after radiotherapy). Last follow-up visit BMI was higher in both groups (P = 0.0001), and obesity incidence was higher for SS (46.2%) than NSS (17.4%). Conclusion: We found a high incidence of early-onset endocrine disorders. An endocrine consultation and nutritional evaluation should be mandatory for all patients with a brain tumor, especially when the tumor is suprasellar or after hypothalamus/pituitary irradiation.
AB - Context: Endocrine complications are common in pediatric brain tumor patients. Objective: We aimed to describe the endocrine follow-up of patients with primary brain tumors. Methods: This is a noninterventional observational study based on data collection from medical records of 221 patients followed at a Pediatric Endocrinology Department. Results: Median age at diagnosis was 6.7 years (range, 0-15.9), median follow-up 6.7 years (0.3-26.6), 48.9% female. Main tumor types were medulloblastoma (37.6%), craniopharyngioma (29.0%), and glioma (20.4%). By anatomic location, 48% were suprasellar (SS) and 52% non-suprasellar (NSS). Growth hormone deficiency (GHD) prevalence was similar in both groups (SS: 83.0%, NSS: 76.5%; P = 0.338), appearing at median 1.8 years (-0.8 to 12.4) after diagnosis; postradiotherapy GHD appeared median 1.6 years after radiotherapy (0.2-10.7). Hypothyroidism was more prevalent in SS (76.4%), than NSS (33.9%) (P < 0.001), as well as ACTH deficiency (SS: 69.8%, NSS: 6.1%; P < 0.001). Early puberty was similar in SS (16%) and NSS (12.2%). Hypogonadotropic hypogonadism was predominant in SS (63.1%) vs NSS (1.3%), P < 0.001, and postchemotherapy gonadal toxicity in NSS (29.6%) vs SS (2.8%), P < 0.001. Adult height was lower for NSS compared to target height (-1.0 SD, P < 0.0001) and to SS patients (P < 0.0001). Thyroid nodules were found in 13/45 patients (28.8%), including 4 cancers (4.8-11.5 years after radiotherapy). Last follow-up visit BMI was higher in both groups (P = 0.0001), and obesity incidence was higher for SS (46.2%) than NSS (17.4%). Conclusion: We found a high incidence of early-onset endocrine disorders. An endocrine consultation and nutritional evaluation should be mandatory for all patients with a brain tumor, especially when the tumor is suprasellar or after hypothalamus/pituitary irradiation.
KW - Brain tumor
KW - childhood cancer
KW - endocrine disorders
KW - non-suprasellar
KW - suprasellar
UR - http://www.scopus.com/inward/record.url?scp=85128493916&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgab893
DO - 10.1210/clinem/dgab893
M3 - Article
C2 - 34918112
AN - SCOPUS:85128493916
SN - 0021-972X
VL - 107
SP - E2156-E2166
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 5
ER -